CJC-1295 and Ipamorelin: What They Are and What the Research Shows

CJC-1295 and Ipamorelin are two man-made peptides that researchers often combine. Both tell the body to release more of its own growth hormone, called GH. They do this through two different signals, which is why they are studied together. They do not add growth hormone from outside the body. Instead, they nudge the pituitary gland — a pea-sized gland at the base of the brain — to make and release more on its own.

CJC-1295 is a copy of growth hormone-releasing hormone, or GHRH. GHRH is the natural signal your brain sends to start GH release. CJC-1295 mimics that signal, but it can last much longer in the body than the natural version. Think of it as the part that keeps the GH signal switched on for a while.

Ipamorelin is a short peptide made of five amino acids. It works on a separate switch called the ghrelin receptor. When it flips that switch, the pituitary releases a quick pulse of GH. Researchers call Ipamorelin "selective" because, in early studies, it raised GH without raising stress hormones like cortisol or prolactin (Raun et al., 1998).

The two peptides are combined because they push GH release in different ways. CJC-1295 acts like a steady, longer push. Ipamorelin acts like a fast, short pulse. People often call this a "pulse and sustain" pattern. The goal is to copy the body's natural GH rhythm a little more closely than either one alone.

One of the most confusing parts of this topic is "DAC." DAC stands for Drug Affinity Complex. It is an add-on that makes CJC-1295 stick to a blood protein called albumin. That makes it last much longer in the body.

CJC-1295 with DAC has a very long half-life. In one human study, GH and IGF-1 stayed raised for several days after a single shot (Teichman et al., 2006). CJC-1295 without DAC is often sold as "Mod GRF 1-29." It clears the body in minutes. Many people who buy a "CJC-1295 + Ipamorelin" blend are actually using the no-DAC form. The two are not the same, and mixing them up is a common mistake.

In the research-use peptide market, this pair is discussed for a few main reasons. People connect it to recovery, body composition, and sleep. These ideas come from the known effects of growth hormone, plus user reports. They are not the same as proven results in trials.

Here is the honest split. Growth hormone itself is well studied. But this specific peptide pair has very little direct human evidence for these goals. Popularity is high. Proof is thin. Both things are true at the same time.

Start with the strongest evidence. CJC-1295 (the DAC form) was tested in two small, placebo-controlled human studies in 2006. A single shot raised GH by about 2 to 10 times for six or more days. IGF-1, a marker tied to GH, stayed up for 9 to 11 days. No serious side effects were reported (Teichman et al., 2006).

Ipamorelin's main evidence is older and mostly from animals. The 1998 study that named it showed clean GH release without raising cortisol or prolactin (Raun et al., 1998). It reached early human testing but was never developed into an approved drug, and a company trial for a gut condition was stopped.

People often compare this pair to other growth-hormone peptides. They are related, but not the same.

Most reported effects are mild and tied to higher GH or IGF-1. Common reports include water retention, tingling or numbness in the hands, headache, and tiredness. Redness or itching at the injection site can also happen.

There are also risks that need real monitoring. Higher IGF-1 over time could affect blood sugar and insulin sensitivity. People with a history of cancer are usually told to avoid GH-raising compounds, because GH and IGF-1 can affect cell growth. These concerns come from GH biology, not from long trials of this exact pair.

Here is the status as of June 2026. Neither CJC-1295 nor Ipamorelin is an FDA-approved drug. Neither one finished the full approval process.

Their compounding status has moved a lot. In late 2023, the FDA placed many peptides, including these two, on a restricted "Category 2" bulk list. In September 2024, both were removed from Category 2 after the nominations were withdrawn. In April 2026, the FDA reorganized its lists again, and these peptides were not placed on the cleared "Category 1" list. The FDA also scheduled advisory committee meetings in 2026 to keep reviewing peptide compounding.

Bottom line: the rules are unsettled, and most CJC-1295 and Ipamorelin sold online is labeled research-use only. For the latest, see our FDA Category 2 update.

If you are researching suppliers, focus on testing, not hype. Look for a recent third-party certificate of analysis (COA) that matches the exact batch. Independent labs like Janoshik test peptide purity. Match the lot number on the vial to the report.

Be careful with words like "safe," "medical grade," or "guaranteed." Those are marketing terms, not proof. Confirm the current supplier policy and testing before any order. You can compare options on our Suppliers hub.